Silence Therapeutics plc
SLNCF
$2.00
$0.2514.29%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -78.62% | -29.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -78.62% | -29.02% | |||
| Cost of Revenue | -81.25% | -24.71% | |||
| Gross Profit | -76.84% | -31.65% | |||
| SG&A Expenses | -35.57% | 12.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -46.83% | 16.24% | |||
| Operating Income | 46.62% | -16.74% | |||
| Income Before Tax | 43.84% | 23.36% | |||
| Income Tax Expenses | -100.00% | -90.00% | |||
| Earnings from Continuing Operations | 43.84% | 23.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.84% | 23.38% | |||
| EBIT | 46.62% | -16.74% | |||
| EBITDA | 46.74% | -16.82% | |||
| EPS Basic | 43.84% | 23.38% | |||
| Normalized Basic EPS | 43.85% | 19.46% | |||
| EPS Diluted | 43.84% | 23.38% | |||
| Normalized Diluted EPS | 43.85% | 19.46% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||